Sarmen Sarkissian, MD In a recent publication in The Lancet Oncology, findings from a phase I clinical trial were reported. Dr Pernas and team reported on the use of a combination of the CXCR4 receptor antagonist, Balixafortide plus the anthracycline eribulin in patients previously treated Her2 negative metastatic breast cancer. The CXCR4 stromal derived factor I-L4 axis, SDF-1a, axis is implicated in regulating immune cells in the tumor microenvironment. 56 patients were enrolled in [...]
